Health Care·Biotechnology·$5.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.73 | N/A | -11.28% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.73 | N/A | -11.28% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions impacting performance. They highlighted a focus on strategic initiatives moving forward.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
The earnings report indicates that Apellis Pharmaceuticals is facing challenges, as evidenced by the missed EPS target. The stock reacted negatively, dropping 3.32% in response to the results and management's cautious tone during the earnings call. Investors may need to consider the company's current operational hurdles as they assess future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WORKDAY INC A
Feb 26, 2024